
NYSE:PG
This summary was created by AI, based on 12 opinions in the last 12 months.
Experts express a cautionary view on Procter & Gamble (PG), highlighting challenges in the consumer sector amid rising input costs and economic uncertainties. While the company remains a reputable dividend aristocrat with a near 3% yield, many analysts are hesitant due to its recent 14.4% decline over the past year and the expectation of modest growth, which is around 4.5%. Despite these challenges, some experts view PG's robust brand portfolio as a strength, indicating that the stock may bounce back in the long term due to its defensive nature amid potential economic downturns. There is a sentiment that PG may be a solid buy as it trades at an attractive valuation, although considerable risks remain in the consumer staples sector, leading to a mixed outlook for substantial returns.
PG vs. JNJ JNJ valuation of 16-17x earnings is cheaper than PG. JNJ has 3 areas: medical devices, healthcare, pharma. PG is just consumer products, trading at 23x earnings. More opportunity in JNJ, with a caveat on the talc lawsuits. JNJ's medical device side should do well post-Covid. Dividends similar in the 2.5% range.
He owns Unilever for their global exposure. P&G beat earnings but their revenues were down. It's trading like a growth stock even though it isn't. They have been coming out with new products. There is progress in grooming products but their baby care has been struggling. He also doesn't like their compliance and ethics. They reward 10% of their float to their executives and not helping employees. They are also make polluting products like Pampers and Swiffers.